MSD has reported that the randomised Phase III KEYNOTE-B96 trial of Keytruda (pembrolizumab) plus chemotherapy (paclitaxel), ...

The KEYNOTE-B96 study of pembrolizumab plus paclitaxel in recurrent platinum-resistant ovarian cancer has met its primary end ...

Merck’s Phase III KEYNOTE-B96 trial shows significant overall and progression-free survival gains with Keytruda plus ...

Merck's Phase 3 trial of Keytruda plus chemo met progression-free survival and overall survival goals in platinum-resistant ...

Merck (MRK) stock gains as its bestselling drug, Keytruda, as part of a combination regimen, succeeds in a Phase 3 trial for ...

Merck’s Keytruda, with more than 40 approved indications, hasn’t yet been able to crack specifically into ovarian cancer. | ...

In the phase 2/3 REFRαME-O1 trial, luveltamab tazevibulin showed encouraging responses in patients with ovarian cancer with ...

US pharma giant Merck & Co (NYSE: MRK) today announced that the Phase III KEYNOTE-B96 trial, also known as ENGOT-ov65, met ...

Researchers from USask have identified a potential target for eliminating breast cancer cells. The team was led by Dr. Franco ...

Albert Einstein College of Medicine and Teva Pharmaceuticals, in collaboration with multiple international institutions, ...